Joseph M Mccune

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6887437/publications.pdf

Version: 2024-02-01

171 papers 20,980 citations

72 h-index 140 g-index

188 all docs

188 docs citations

188 times ranked 20724 citing authors

#	Article	IF	CITATIONS
1	IFN- $\hat{l}\pm$ blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. JCI Insight, 2022, 7, .	5.0	6
2	Bringing Gene Therapies for HIV Disease to Resource-Limited Parts of the World. Human Gene Therapy, 2021, 32, 21-30.	2.7	8
3	The case for an HIV cure and how to get there. Lancet HIV,the, 2021, 8, e51-e58.	4.7	46
4	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight, 2021, 6, .	5.0	43
5	Collaborative science to advance gene therapies in resource-limited parts of the world. Molecular Therapy, 2021, 29, 3101-3102.	8.2	7
6	HIV-1 Genomes Are Enriched in Memory CD4 ⁺ T-Cells with Short Half-Lives. MBio, 2021, 12, e0244721.	4.1	11
7	Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV,the, 2021, 8, e42-e50.	4.7	38
8	Single-Cell Mapping of Progressive Fetal-to-Adult Transition in Human Naive T Cells. Cell Reports, 2021, 34, 108573.	6.4	25
9	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	4.7	25
10	CD57+ Memory T Cells Proliferate InÂVivo. Cell Reports, 2020, 33, 108501.	6.4	18
11	Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection. Cell Reports, 2020, 31, 107494.	6.4	31
12	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
13	Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post–Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight. Journal of Immunology, 2019, 203, 899-910.	0.8	11
14	HIV "cure― A shot in the arm?. EBioMedicine, 2019, 42, 3-5.	6.1	11
15	The Ban on US Government Funding Research Using Human Fetal Tissues: How Does This Fit with the NIH Mission to Advance Medical Science for the Benefit of the Citizenry?. Stem Cell Reports, 2019, 13, 777-786.	4.8	23
16	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 211-219.	2.1	14
17	Why and where an HIV cure is needed and how it might be achieved. Nature, 2019, 576, 397-405.	27.8	90
18	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. Pathogens and Immunity, 2019, 4, 147.	3.1	15

#	Article	IF	Citations
19	Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. Journal of Histochemistry and Cytochemistry, 2018, 66, 427-446.	2.5	19
20	Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. Journal of Immunology, 2018, 200, 1124-1132.	0.8	4
21	Glut1 Expression Level on Inflammatory Monocytes is Associated With Markers of Cardiovascular Disease Risk in HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e28-e30.	2.1	8
22	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Human Molecular Genetics, 2018, 27, 3813-3824.	2.9	43
23	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathogens, 2018, 14, e1006806.	4.7	12
24	Relative mRNA Expression Levels of Restriction Factors and Antiviral Genes in Fetal and Adult Human Monocytes and Monocyte-Derived Macrophages. Viral Immunology, 2017, 30, 142-148.	1.3	3
25	Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes, 2017, 8, 440-450.	9.8	56
26	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Research and Human Retroviruses, 2017, 33, 658-667.	1.1	22
27	Defining total-body AIDS-virus burden with implications for curative strategies. Nature Medicine, 2017, 23, 1271-1276.	30.7	322
28	Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during <i>inÂvitro</i> infection. FEBS Letters, 2017, 591, 3319-3332.	2.8	56
29	Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. Cell Reports, 2017, 20, 984-998.	6.4	66
30	IL-21 Therapy Controls Immune Activation and Maintains Antiviral CD8 ⁺ T Cell Responses in Acute Simian Immunodeficiency Virus Infection. AIDS Research and Human Retroviruses, 2017, 33, S-81-S-92.	1.1	17
31	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	8.4	186
32	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. Journal of Clinical Investigation, 2016, 126, 2745-2756.	8.2	97
33	A Cure for HIV Infection: "Not in My Lifetime―or "Just Around the Corner�. Pathogens and Immunity, 2016, 1, 154.	3.1	35
34	Impact of early cART in the gut during acute HIV infection. JCI Insight, 2016, 1, .	5.0	56
35	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
36	Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing. Journal of Virology, 2016, 90, 6255-6262.	3.4	13

#	Article	IF	CITATIONS
37	Henry Kunkel and the teaching of patient-oriented research. Clinical Immunology, 2016, 172, 27-28.	3.2	О
38	Lin 28b Regulates Fetal Regulatory T Cell Differentiation through Modulation of TGF- \hat{l}^2 Signaling. Journal of Immunology, 2016, 197, 4344-4350.	0.8	34
39	A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood. Journal of Visualized Experiments, 2016, , .	0.3	5
40	Immunologic profiles distinguish aviremic HIV-infected adults. Aids, 2016, 30, 1553-1562.	2.2	22
41	Eye examination for early diagnosis of disseminated tuberculosis in patients with AIDS. Lancet Infectious Diseases, The, 2016, 16, 493-499.	9.1	26
42	Defining HIV and SIV Reservoirs in Lymphoid Tissues. Pathogens and Immunity, 2016, 1, 68.	3.1	212
43	Gut-Resident Lactobacillus Abundance Associates with IDO1 Inhibition and Th17 Dynamics in SIV-Infected Macaques. Cell Reports, 2015, 13, 1589-1597.	6.4	75
44	Gut epithelial barrier and systemic inflammation during chronic HIV infection. Aids, 2015, 29, 43-51.	2.2	156
45	Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge. Science Translational Medicine, 2015, 7, 300ra125.	12.4	7
46	Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL- $1\hat{l}^2$: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease. Journal of Immunology, 2015, 195, 4096-4105.	0.8	3
47	Glucocorticoid Treatment at Moderate Doses of SIV _{mac251} -Infected Rhesus Macaques Decreases the Frequency of Circulating CD14 ⁺ CD16 ⁺⁺ Monocytes But Does Not Alter the Tissue Virus Reservoir. AIDS Research and Human Retroviruses, 2015, 31, 115-126.	1.1	15
48	Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging. PLoS ONE, 2014, 9, e89444.	2.5	85
49	Distinct Functional Programs in Fetal T and Myeloid Lineages. Frontiers in Immunology, 2014, 5, 314.	4.8	13
50	Analysis of maternal microchimerism in rhesus monkeys (<i>Macaca mulatta</i>) using real-time quantitative PCR amplification of MHC polymorphisms. Chimerism, 2014, 5, 6-15.	0.7	14
51	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. PLoS Pathogens, 2014, 10, e1004078.	4.7	495
52	The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 210, 383-391.	4.0	101
53	Glucose Transporter 1–Expressing Proinflammatory Monocytes Are Elevated in Combination Antiretroviral Therapy–Treated and Untreated HIV+ Subjects. Journal of Immunology, 2014, 193, 5595-5603.	0.8	78
54	Myeloidâ€Lymphoid Ontogeny in the Rhesus Monkey (<i>Macaca mulatta</i>). Anatomical Record, 2014, 297, 1392-1406.	1.4	26

#	Article	IF	CITATIONS
55	Low Proportions of CD28â^' CD8+ T cells Expressing CD57 Can Be Reversed by Early ART Initiation and Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 374-382.	4.0	53
56	Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4+ T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Research and Therapy, 2014, 11, 27.	1.7	2
57	Distinct functional programming of human fetal and adult monocytes. Blood, 2014, 123, 1897-1904.	1.4	47
58	Humanized Mice as Models for Human Disease. , 2014, , 15-24.		1
59	Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease. PLoS ONE, 2014, 9, e85613.	2.5	41
60	Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production. PLoS ONE, 2014, 9, e87877.	2.5	106
61	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e116306.	2.5	56
62	Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. Science Translational Medicine, 2013, 5, 193ra91.	12.4	578
63	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. Journal of Infectious Diseases, 2013, 208, 1202-1211.	4.0	285
64	IL-7 production in murine lymphatic endothelial cells and induction in the setting of peripheral lymphopenia. International Immunology, 2013, 25, 471-483.	4.0	59
65	Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. PLoS Pathogens, 2013, 9, e1003691.	4.7	94
66	Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. Journal of Infectious Diseases, 2013, 208, 1436-1442.	4.0	151
67	Preclinical Evaluation of HIV Eradication Strategies in the Simian Immunodeficiency Virus-Infected Rhesus Macaque: A Pilot Study Testing Inhibition of Indoleamine 2,3-Dioxygenase. AIDS Research and Human Retroviruses, 2013, 29, 207-214.	1.1	16
68	Higher CD27+CD8+ T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4+ T Cell Recovery in Treated HIV Infection. PLoS ONE, 2013, 8, e84091.	2.5	9
69	Therapeutic Helminth Infection of Macaques with Idiopathic Chronic Diarrhea Alters the Inflammatory Signature and Mucosal Microbiota of the Colon. PLoS Pathogens, 2012, 8, e1003000.	4.7	206
70	Correction: Central Memory CD8+ T Cells Appear to Have a Shorter Lifespan and Reduced Abundance as a Function of HIV Disease Progression. Journal of Immunology, 2012, 189, 5089-5089.	0.8	0
71	Morphine Produces Immunosuppressive Effects in Nonhuman Primates at the Proteomic and Cellular Levels. Molecular and Cellular Proteomics, 2012, 11, 605-618.	3.8	45
72	SIV Replication in the Infected Rhesus Macaque Is Limited by the Size of the Preexisting T _H 17 Cell Compartment. Science Translational Medicine, 2012, 4, 136ra69.	12.4	34

#	Article	IF	Citations
73	A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. Aids, 2012, 26, 805-814.	2.2	83
74	Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. Blood, 2012, 119, 3469-3477.	1.4	36
75	Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease. Cell Stem Cell, 2012, 10, 137-147.	11.1	110
76	Immunosenescence and HIV. Current Opinion in Immunology, 2012, 24, 501-506.	5. 5	126
77	Immunological Tolerance During Fetal Development. Advances in Immunology, 2012, 115, 73-111.	2.2	122
78	A functional variant in <i>FCRL3</i> is associated with higher Fc receptor–like 3 expression on T cell subsets and rheumatoid arthritis disease activity. Arthritis and Rheumatism, 2012, 64, 2451-2459.	6.7	22
79	Breaking Free of Sample Size Dogma to Perform Innovative Translational Research. Science Translational Medicine, 2011, 03, 87ps24.	12.4	122
80	A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers. PLoS ONE, 2011, 6, e15924.	2.5	122
81	Th17 cells and regulatory T cells in elite control over HIV and SIV. Current Opinion in HIV and AIDS, 2011, 6, 221-227.	3.8	76
82	HIV disease progression correlates with the generation of dysfunctional naive CD8low T cells. Blood, 2011, 117, 2189-2199.	1.4	30
83	Measurement of absolute T cell receptor rearrangement diversity. Journal of Immunological Methods, 2011, 368, 45-53.	1.4	8
84	Design, construction, and validation of a modular library of sequence diversity standards for polymerase chain reaction. Analytical Biochemistry, 2011, 411, 106-115.	2.4	8
85	At the crossroads between tolerance and aggression. Chimerism, 2011, 2, 35-41.	0.7	36
86	HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV Controllers. Clinical Infectious Diseases, 2011, 52, 681-687.	5.8	33
87	The Human Fetal Immune Response to Hepatitis C Virus Exposure in Utero. Journal of Infectious Diseases, 2011, 203, 196-206.	4.0	45
88	Immune Activation, Cd4+ T Cell Counts, and Viremia Exhibit Oscillatory Patterns over Time in Patients with Highly Resistant HIV Infection. PLoS ONE, 2011, 6, e21190.	2.5	12
89	Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood, 2010, 115, e20-e32.	1.4	36
90	Can HIV be cured with stem cell therapy?. Nature Biotechnology, 2010, 28, 807-810.	17. 5	25

#	Article	IF	Citations
91	Cytomegalovirus-Specific T Cells Persist at Very High Levels during Long-Term Antiretroviral Treatment of HIV Disease. PLoS ONE, 2010, 5, e8886.	2.5	176
92	Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T $<$ sub $>$ H $<$ /sub $>$ 17 to Regulatory T Cells in HIV Disease. Science Translational Medicine, 2010, 2, 32ra36.	12.4	454
93	Fetal and Adult Hematopoietic Stem Cells Give Rise to Distinct T Cell Lineages in Humans. Science, 2010, 330, 1695-1699.	12.6	379
94	Expression of the Autoimmune Susceptibility Gene FcRL3 on Human Regulatory T Cells Is Associated with Dysfunction and High Levels of Programmed Cell Death-1. Journal of Immunology, 2010, 184, 3639-3647.	0.8	75
95	IL-22 ⁺ CD4 ⁺ T Cells Are Associated with Therapeutic <i>Trichuris trichiura</i> Infection in an Ulcerative Colitis Patient. Science Translational Medicine, 2010, 2, 60ra88.	12.4	180
96	Naive Human T Cells Are Activated and Proliferate in Response to the Heme Oxygenase-1 Inhibitor Tin Mesoporphyrin. Journal of Immunology, 2010, 185, 5279-5288.	0.8	32
97	IFN-α-Induced Upregulation of CCR5 Leads to Expanded HIV Tropism In Vivo. PLoS Pathogens, 2010, 6, e1000766.	4.7	42
98	Th17 and regulatory T cells: implications for AIDS pathogenesis. Current Opinion in HIV and AIDS, 2010, 5, 151-157.	3.8	137
99	Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy. Journal of Virology, 2009, 83, 329-335.	3.4	191
100	Critical Loss of the Balance between Th17 and T Regulatory Cell Populations in Pathogenic SIV Infection. PLoS Pathogens, 2009, 5, e1000295.	4.7	355
101	Transcriptional Profiling in Pathogenic and Non-Pathogenic SIV Infections Reveals Significant Distinctions in Kinetics and Tissue Compartmentalization. PLoS Pathogens, 2009, 5, e1000296.	4.7	121
102	Gag p27-Specific B- and T-Cell Responses in Simian Immunodeficiency Virus SIVagm-Infected African Green Monkeys. Journal of Virology, 2009, 83, 2770-2777.	3.4	22
103	Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells. Journal of Biological Chemistry, 2009, 284, 6782-6789.	3.4	252
104	Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clinical Immunology, 2009, 132, 124-131.	3.2	75
105	Effect of SIVmac infection on plasmacytoid and CD1c ⁺ myeloid dendritic cells in cynomolgus macaques. Immunology, 2008, 124, 223-233.	4.4	41
106	In vivo imaging of mucosal CD4+ T cells using single photon emission computed tomography in a murine model of colitis. Journal of Immunological Methods, 2008, 329, 21-30.	1.4	38
107	Relationship between T Cell Activation and CD4 ⁺ T Cell Count in HIVâ€Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. Journal of Infectious Diseases, 2008, 197, 126-133.	4.0	579
108	Maternal Alloantigens Promote the Development of Tolerogenic Fetal Regulatory T Cells in Utero. Science, 2008, 322, 1562-1565.	12.6	749

#	Article	IF	Citations
109	Central Memory CD8+ T Cells Appear to Have a Shorter Lifespan and Reduced Abundance as a Function of HIV Disease Progression. Journal of Immunology, 2008, 180, 7907-7918.	0.8	67
110	HIV-Induced Changes in T Cell Signaling Pathways. Journal of Immunology, 2008, 180, 6490-6500.	0.8	35
111	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. Journal of Experimental Medicine, 2008, 205, 2763-2779.	8.5	681
112	Apolipoprotein (apo) E4 enhances HIV-1 cell entry <i>in vitro</i> , and the <i>APOE</i> $\hat{\mu}4/\hat{\mu}4$ genotype accelerates HIV disease progression. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8718-8723.	7.1	181
113	Growth hormone enhances thymic function in HIV-1–infected adults. Journal of Clinical Investigation, 2008, 118, 1085-98.	8.2	143
114	Suppression of SIV-specific CD4+ T cells by infant but not adult macaque regulatory T cells: implications for SIV disease progression. Journal of Experimental Medicine, 2007, 204, 2679-2692.	8.5	46
115	Antiviral Antibodies Are Necessary for Control of Simian Immunodeficiency Virus Replication. Journal of Virology, 2007, 81, 5024-5035.	3.4	73
116	Dehydroepiandrosterone (DHEA) Effects on HIV Replication and Host Immunity: A Randomized Placebo-Controlled Study. AIDS Research and Human Retroviruses, 2007, 23, 77-85.	1.1	25
117	Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. Journal of Immunological Methods, 2007, 319, 41-52.	1.4	256
118	Loss of T cell responses following long-term cryopreservation. Journal of Immunological Methods, 2007, 326, 93-115.	1.4	88
119	Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses. Journal of Virology, 2006, 80, 6155-6164.	3.4	127
120	Regulation of T Cell Responses in the Developing Human Fetus. Journal of Immunology, 2006, 176, 5741-5748.	0.8	219
121	Direct measurement of T-cell receptor repertoire diversity with AmpliCot. Nature Methods, 2006, 3, 895-901.	19.0	21
122	HIV-1-Specific CD4+ T Cell Responses in Chronically HIV-1 Infected Blippers on Antiretroviral Therapy in Relation to Viral Replication Following Treatment Interruption. Journal of Clinical Immunology, 2006, 26, 40-54.	3.8	19
123	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Aids, 2006, 20, 2275-2283.	2.2	239
124	A Plea for Justice for Jailed Medical Workers. Science, 2006, 314, 924-925.	12.6	3
125	Prevalence of CXCR4 Tropism among Antiretroviralâ€Treated HIVâ€1–Infected Patients with Detectable Viremia. Journal of Infectious Diseases, 2006, 194, 926-930.	4.0	137
126	Growth Hormone-Induced Stimulation of Multilineage Human Hematopoiesis. Stem Cells, 2005, 23, 1170-1179.	3.2	44

#	Article	IF	CITATIONS
127	Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. Journal of Virology, 2005, 79, 14169-14178.	3.4	207
128	Multiparameter evaluation of human thymic function: interpretations and caveats. Clinical Immunology, 2005, 115, 138-146.	3.2	75
129	PUBLIC HEALTH: Enhanced: A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials. Science, 2004, 303, 316-316.	12.6	123
130	Strong Cellâ€Mediated Immune Responses Are Associated with the Maintenance of Lowâ€Level Viremia in Antiretroviral–Treated Individuals with Drugâ€Resistant Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 2004, 189, 312-321.	4.0	90
131	Gene expression profiles during human CD4+ T cell differentiation. International Immunology, 2004, 16, 1109-1124.	4.0	80
132	Isolation of peripheral blood CD4+ T cells using RosetteSepâ,,¢ and MACSâ,,¢ for studies of DNA turnover by deuterium labeling. Journal of Immunological Methods, 2004, 286, 97-109.	1.4	33
133	Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. Aids, 2004, 18, 1953-1956.	2.2	34
134	Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. Journal of Immunological Methods, 2003, 283, 141-153.	1.4	200
135	Human Immunodeficiency Virus Type 1 Nef-Mediated Downregulation of CD4 Correlates with Nef Enhancement of Viral Pathogenesis. Journal of Virology, 2003, 77, 2124-2133.	3.4	92
136	Effects of IL-7 on Early Human Thymocyte Progenitor Cells In Vitro and in SCID-hu Thy/Liv Mice. Journal of Immunology, 2003, 171, 645-654.	0.8	43
137	Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection. Annals of Internal Medicine, 2003, 139, 258.	3.9	200
138	Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. Journal of Clinical Investigation, 2003, 112, 956-966.	8.2	104
139	Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. Journal of Clinical Investigation, 2003, 112, 956-966.	8.2	195
140	Generation of CD3+CD8low Thymocytes in the HIV Type 1-Infected Thymus. Journal of Immunology, 2002, 169, 2788-2796.	0.8	40
141	IFN-α Secretion by Type 2 Predendritic Cells Up-Regulates MHC Class I in the HIV-1-Infected Thymus. Journal of Immunology, 2002, 168, 325-331.	0.8	87
142	Shortâ€Term Effects of Cannabinoids on Immune Phenotype and Function in HIVâ€1â€Infected Patients. Journal of Clinical Pharmacology, 2002, 42, 82S-89S.	2.0	59
143	Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. Aids, 2002, 16, 1103-1111.	2.2	140
144	Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia. New England Journal of Medicine, 2001, 344, 472-480.	27.0	672

#	Article	IF	Citations
145	Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. Aids, 2001, 15, 1749-1756.	2.2	215
146	Increased production of IL-7 accompanies HIV-1–mediated T-cell depletion: implications for T-cell homeostasis. Nature Medicine, 2001, 7, 73-79.	30.7	498
147	Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nature Medicine, 2001, 7, 712-718.	30.7	141
148	The dynamics of CD4+ T-cell depletion in HIV disease. Nature, 2001, 410, 974-979.	27.8	488
149	Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. Journal of Immunological Methods, 2001, 255, 27-40.	1.4	343
150	Loss of Cytomegalovirusâ€Specific CD4+T Cell Responses in Human Immunodeficiency Virus Type 1–Infected Patients with High CD4+T Cell Counts and Recurrent Retinitis. Journal of Infectious Diseases, 2001, 183, 1285-1289.	4.0	112
151	A Membrane-bound Fas Decoy Receptor Expressed by Human Thymocytes. Journal of Biological Chemistry, 2000, 275, 7988-7993.	3.4	38
152	Antiviral Activity of 2′-Deoxy-3′-Oxa-4′-Thiocytidine (BCH-10652) against Lamivudine-Resistant Human Immunodeficiency Virus Type 1 in SCID-hu Thy/Liv Mice. Antimicrobial Agents and Chemotherapy, 2000, 44, 783-786.	3.2	37
153	Coinfection of SCID-hu Thy/Liv Mice with Human Herpesvirus 6 and Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 8726-8731.	3.4	20
154	Factors influencing T-cell turnover in HIV-1–seropositive patients. Journal of Clinical Investigation, 2000, 105, R1-R8.	8.2	207
155	Human Herpesvirus 6 (HHV-6) Causes Severe Thymocyte Depletion in SCID-hu Thy/Liv Mice. Journal of Experimental Medicine, 1999, 189, 1953-1960.	8.5	53
156	Direct Evidence for Thymic Function in Adult Humans. Journal of Experimental Medicine, 1999, 190, 479-486.	8.5	218
157	R5 Strains of Human Immunodeficiency Virus Type 1 from Rapid Progressors Lacking X4 Strains Do Not Possess X4-Type Pathogenicity in Human Thymus. Journal of Virology, 1999, 73, 7817-7822.	3.4	20
158	Furry flasks?. Nature Biotechnology, 1998, 16, 314-314.	17.5	0
159	Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Medicine, 1998, 4, 953-956.	30.7	395
160	UV Irradiation of Polystyrene Pipets Releases PCR Inhibitors. BioTechniques, 1998, 24, 50-52.	1.8	8
161	Inhibition of Human Immunodeficiency Virus Type 1 Infection in SCID-hu Thy/Liv Mice by the G-Quartet-Forming Oligonucleotide, ISIS 5320. Antimicrobial Agents and Chemotherapy, 1998, 42, 2113-2115.	3.2	29
162	CCR5- and CXCR4-Utilizing Strains of Human Immunodeficiency Virus Type 1 Exhibit Differential Tropism and Pathogenesis In Vivo. Journal of Virology, 1998, 72, 10108-10117.	3.4	98

#	Article	IF	CITATIONS
163	Thymic function in HIV-1 disease. Seminars in Immunology, 1997, 9, 397-404.	5.6	63
164	Viral latency in HIV disease. Cell, 1995, 82, 183-188.	28.9	78
165	Development of a Human Thymic Organ Culture Model for the Study of HIV Pathogenesis. AIDS Research and Human Retroviruses, 1995, 11, 1073-1080.	1.1	53
166	Human hematolymphoid cells in SCID mice. Current Opinion in Immunology, 1994, 6, 327-333.	5. 5	37
167	HIV induces thymus depletion in vivo. Nature, 1993, 363, 728-732.	27.8	420
168	SCID mice as immune system models. Current Opinion in Immunology, 1991, 3, 224-228.	5.5	25
169	Postexposure Prophylaxis with Zidovudine Suppresses Human Immunodeficiency Virus Type 1 Infection in SCID-hu Mice in a Time-Dependent Manner. Journal of Infectious Diseases, 1991, 163, 625-627.	4.0	121
170	Suppression of HIV infection in AZT-treated SCID-hu mice. Science, 1990, 247, 564-566.	12.6	208
171	Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell, 1988, 53, 55-67.	28.9	695